PDCD1 and neoplasm: The combination of decitabine, IR700DX-6T-PDT, and an anti-PD-1 antibody overcame the immunosuppressive environment and reduced tumor volume in vivo in experimental animals, thus offering a promising strategy for the therapy of “cold” tumors [92].